Novo Nordisk is expanding its efforts to sell its obesity drug Wegovy directly to patients, striking agreements with telehealth companies including Hims & Hers, Ro, and LifeMD.
Novo last month launched a new direct-to-consumer website called NovoCare Pharmacy that sells Wegovy, which normally carries a list price of about $1,350 a month, at $499 a month to patients who are paying on their own without insurance. With the new deals, patients can order this lower-priced Wegovy directly on the telehealth companies’ sites and get the treatment delivered to their homes.
Novo is following in the footsteps of competitor Eli Lilly, which began selling its obesity drug Zepbound with telehealth companies at a lower cost last year.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
